JAZZ Stock: Price, Earnings History and SEC Filings
Jazz Pharmaceuticals plc (JAZZ) last traded at $215.98, up 3.92% on the latest session and down 6.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $4.89 against an analyst estimate of $5.06, a miss of 3.4%.
$215.98 +3.92%
1 month-6.71%
52-week high$266.38
52-week low$128.80
Volume1.22M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
JAZZ earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $4.89 | $5.06 | -3.36% |
| Mar 2026 | May 5, 2026 | $5.46 | $3.82 | +42.93% |
| Dec 2025 | Feb 24, 2026 | $5.76 | $5.65 | +1.95% |
| Sep 2025 | Nov 5, 2025 | $6.99 | $4.80 | +45.63% |
JAZZ beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for JAZZ
SEC filing data is not available right now. You can search for JAZZ on SEC EDGAR.
JAZZ news
- What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earningsNov 1, 2026 · finance.yahoo.com
- 3 Biotech Stocks With Upside Of Up To 80%Oct 31, 2026 · finance.yahoo.com
- With Setara, the team behind Actio opens its second actOct 30, 2026 · biopharmadive.com
- Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion IndicationsOct 30, 2026 · finance.yahoo.com
- Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineOct 27, 2026 · fool.com
- Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 27, 2026 · finance.yahoo.com
- Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forOct 26, 2026 · finance.yahoo.com
- Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026Oct 23, 2026 · finance.yahoo.com
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) is a US-listed public company on Nasdaq.